Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on procedural ...

Novo Nordisk launches recycling programme for pen injectors There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes, making it easier to ...